Marc Tessier-Lavigne on Research at Genentech
  Marc Tessier-Lavigne     Biography    
Recorded: 11 Sep 2008

Well, the Genentech is—the approach that Genentech takes to disease and to the development of medicines is exactly the same approach that as basic scientists we take to a scientific problem. It’s been like that since Genentech was founded in 1976 by Bob Swanson and Herb Boyer. And that culture has remained over the subsequent thirty years including through the leadership of the current CEO Art Levinson who himself is a scientist, which is unusual for a biotech company are a pharmaceutical company. So the culture is entirely scientific. We tackle all problems the way we tackle scientific problems and our approach to understanding disease is grounded in science, our development to medicine is grounded in science. So my training as a basic scientist prepared me perfectly for the approach that Genentech takes to tackling these problems. It may not have prepared me perfectly for other ways that other people may take. But it was a very natural fit and that was attractive of course.

Marc Tessier-Lavigne, a pioneer in developmental neurobiology, is currently president of The Rockefeller University in New York, where he heads the Laboratory of Brain Development and Repair, and oversees 70 independent laboratories that operate within the university. He is the first industry executive to serve as president of Rockefeller. He joined Genentech, Inc. in 2003 as Senior Vice President, Research Drug Discovery, and was promoted to Executive Vice President, Research Drug Discovery in June, 2008. In that capacity, he was responsible for research management of all therapeutic areas of research, including a team of 1,400 researchers and his own research lab. His research at Genentech on the development of the brain uncovered details of how Alzheimer's disease is triggered.

Born in Canada in 1959, he was also raised in Belgium and the UK, and has lived in the US since 1990. Marc completed an undergraduate degree in physics and mathematics from McGill University (B.Sc., 1980), and a second undergraduate degree in philosophy and physiology from Oxford University (Rhodes Scholar, B.A., 1982). Prior to earning his Ph.D. at University College London (1986) in neurophysiology, Marc became the national coordinator of the Canadian Student Pugwash Organization, which promotes awareness and action relating to nuclear non-proliferation and disarmament, and other ethical implications of science and technology policy. During his postdoctoral work at UCL and Columbia University, Marc’s research focus became developmental neurobiology. From 1991 to 2001 he was on the faculty at the University of California, San Francisco.

From 1994 to 2003 he was also an investigator with the Howard Hughes Medical Institute. His famous discovery of the netrins (a class of proteins involved in axon guidance) occurred in 1994 while he was at the University of California, San Francisco. In 2000 he co-founded the biopharmaceutical company Renovis. From 2001-2003 he was the Susan B. Ford Professor in the School of Humanities and Sciences and professor of Biological Sciences and a professor of Neurology and Neurological Sciences at Stanford University.

Among the many awards Marc has received for his work in neuroscience are the McKnight Investigator Award (1994), the Ameritec Prize (1995), the Foundation IPSEN Prize for Neuronal Plasticity (shared, 1996), the Viktor Hamburger Award, International Society for Developmental Neuroscience (1997), the Wakeman Award for spinal cord injury research (shared, 1998), the Robert Dow Neuroscience Award (2003), and the Reeve-Irvine Research Medal (shared, 2006). Tessier-Lavigne has been elected a member of the United States National Academy of Sciences, a fellow of the American Association for the Advancement of Science, a fellow of the Royal Society of Canada, and a fellow of the Royal Society and the Academy of Medical Sciences in the United Kingdom.